Thanh-Trang Vo

Title: The Innovative Contributions of Thanh-Trang Vo in Cancer Therapy

Introduction: Thanh-Trang Vo, based in San Diego, CA, has made significant strides in the field of immunotherapy, focusing on treatments for ROR1 expressing cancers. His inventive spirit and dedication to cancer research exemplify the role of inventors in advancing medical technologies.

Latest Patents: Thanh-Trang Vo holds one notable patent titled "ROR1 antibody immunoconjugates." This patent encompasses immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof paired with a drug moiety. These innovative immunoconjugates are designed to target and treat cancers that express the ROR1 protein, highlighting Vo's contributions to developing targeted therapies.

Career Highlights: Thanh-Trang Vo is currently employed at Velosbio Inc., a company at the forefront of biopharmaceutical development. His work there emphasizes the integration of antibody-based therapies in combating cancer, showcasing his commitment to improving patient outcomes through scientific innovation.

Collaborations: Throughout his career, Thanh-Trang Vo has collaborated with esteemed colleagues, including Brian Lannutti and Katti Jessen. Their collective expertise fosters an environment of innovation, allowing for the sharing of knowledge and ideas that drive the development of groundbreaking cancer treatments.

Conclusion: Thanh-Trang Vo's innovative spirit and dedication to his work at Velosbio Inc. have positioned him as a key figure in the development of therapies targeting ROR1 expressing cancers. His patent on ROR1 antibody immunoconjugates not only showcases his inventive prowess but also holds the potential to make a meaningful impact in the fight against cancer.